Retinal vein occlusion (RVO) is most commonly seen in middle-aged or older patients and is associated with underlying cardiovascular risk factors. It is much less common in younger patients. Use of the oral contra ceptive pill (OCP) is known to be a risk factor for cardiovascular and cerebrovascular disease. There have previously been a few isolated case reports of patients sustaining an RVO whilst taking the OCP. The aim of this study was to investigate patients sustaining an RVO whilst taking the OCP or hormone replacement therapy (HRT). F:rom a large series of 588 patients, we found 11 with an RVO associated with sex hormone prepara tions. Of these, 6 had taken the OCP and 5 were HRT users. From this large group there were only 9 female patients aged under 35 years who sustained an RVO. Of these, 6 were associated with use of the OCP. All patients were investigated for recognised medical risk factors for RVO. None of these factors were identified in the patients who had used the OCP. Of the patients taking HRT, 4 of the 5 had other potential risk factors. From our large series, the prevalence of RVO in female patients under 35 years taking the OCP was 66%. There is a 30% uptake of the OCP in the general population. These data support the view that RVO is a contraindication to the use of the OCP. Additionally, it would appear (albeit from limited data) that patients who sustain RVO may continue with their HRT, as HRT is not a major single risk factor for RVO. intramural formation of thrombus and, secondly, extreme 'phlebosclerosis' with secondary endothelial degeneration. Studies have shown abnormalities in patients with RVO that may predispose to both these mechanisms. These include an increased prevalence of hypertension. hyperlipidaemia, enhanced in vivo platelet activity and the possibility of increased inflammatory activity.
SUMMARY
Retinal vein occlusion (RVO) is most commonly seen in middle-aged or older patients and is associated with underlying cardiovascular risk factors. It is much less common in younger patients. Use of the oral contra ceptive pill (OCP) is known to be a risk factor for cardiovascular and cerebrovascular disease. There have previously been a few isolated case reports of patients sustaining an RVO whilst taking the OCP. The aim of this study was to investigate patients sustaining an RVO whilst taking the OCP or hormone replacement therapy (HRT). F:rom a large series of 588 patients, we found 11 with an RVO associated with sex hormone prepara tions. Of these, 6 had taken the OCP and 5 were HRT users. From this large group there were only 9 female patients aged under 35 years who sustained an RVO. Of these, 6 were associated with use of the OCP. All patients were investigated for recognised medical risk factors for RVO. None of these factors were identified in the patients who had used the OCP. Of the patients taking HRT, 4 of the 5 had other potential risk factors. From our large series, the prevalence of RVO in female patients under 35 years taking the OCP was 66%. There is a 30% uptake of the OCP in the general population. These data support the view that RVO is a contraindication to the use of the OCP. Additionally, it would appear (albeit from limited data) that patients who sustain RVO may continue with their HRT, as HRT is not a major single risk factor for RVO. intramural formation of thrombus and, secondly, extreme 'phlebosclerosis' with secondary endothelial degeneration. Studies have shown abnormalities in patients with RVO that may predispose to both these mechanisms. These include an increased prevalence of hypertension. hyperlipidaemia, enhanced in vivo platelet activity and the possibility of increased inflammatory activity.
RVO does occur in younger patients. with hyperlipidaemia being a more predominant asso ciated factor than hypertension. Additionally, in younger patients, inflammatory causes can be impor tant. From a large series of patients with RVO, predisposing factors in these younger patients were assessed. A number of patients taking sex hormone preparations have been recorded. 4 The aim of this study was to examine the risk factor profile in patients sustaining RVO whilst taking sex hormone preparations, to determine whether the oral contraceptive pill (OCP) or hormone replacement therapy (HRT) could be implicated as independent risk factors in the aetiol ogy of RVO.
METHOD
Five hundred and eighty-eight patients presenting after 1982 with RVO were reviewed in 1994. A number of younger patients were noted to be taking sex hormone preparations. notably the combined OCP and HRT. These patients were divided into two subgroups: (a) those taking the OCP (n = 6) and (b) those taking HRT (n = 5). assessed for the presence of underlying medical conditions. Assessment consisted of consultation with a physician (P.M.D.) with full medical history and examination. The following baseline investiga tions were performed: full blood count, erythrocyte sedimentation rate (or plasma viscosity) , serum fibrinogen, serum urea and electrolytes. blood cholesterol and triglyceride levels, serum immuno globulins, plasma electrophoresis, electrocardiogram and chest radiography. Particular attention was paid to the presence of hypertension, hyperlipidaemia, smoking habits and alcohol consumption, the presence of other medical conditions, and drug therapy. Patients taking the OCP or HRT had their medication stopped, as in the 1980s this treatment was believed to be detrimental.
Definitions for the purpose of this study included that of t . he World Health Organization for hyperten sion (systolic >160 mmHg, diastolic >95 mmHg on three occasions of if the patient was already taking antihypertensive drug therapy). Hyperlipidaemia was defined as fasting serum cholesterol >6.5 mmoll I and/or fasting serum triglyceride levels >2.1 mmolll.
RESULTS
Clinical data obtained on patients taking the OCP are shown in Table I . Ages ranged from 24 to 33 years, with a mean of 27 years 9 months. All but 1 patient was taking the combined oestrogen/progesto gen OCP (COCP); the other patient was taking the progestogen-only pill or 'mini-pill' (POP). Duration of use ranged from 2 to 14 years with a mean of 7 years 4 months. Two of the patients, indicated with an asterisk in Table I , had stopped using the OCP prior to the onset of RVO, the first 11 months and the second 5 months prior to that time.
None of the patients smoked, but two patients were ex-smokers. All but 1 patient consumed less than 16 units of alcohol weekly; the other (no. 3) consumed 28 units weekly. None of the patients was hypertensive, hyperlipidaemic, diabetic, or had any other identified risk factor for RVO. All other blood tests were normal.
Branch retinal vein occlusion (BRVO) was present in 2 patients; 4 had a central retinal vein occlusion (CRVO). Two patients had a poor visual outcome, one with CRVO and one with BRVO. One patient (no. 5 ) had an earlier RVO, continued to take the OCP, and then later had a more extensive recurrent RVO with a poor visual outcome. The data obtained on patients taking HRT are shown in Table II . Ages ranged from 48 to 59 years with a mean of 53 years 6 months. Duration of use ranged from 1 month to 7 years. All were current users of HRT. All patients were taking HRT for relief of menopausal symptoms. Two patients took an oestrogen-only type preparation, the other 3 took a combined oestrogen/progestogen preparation.
Two patients were hypertensive, two patients were smokers, and 1 of these was also hypertensive, on treatment. One patient had a raised serum choles terol of 7.2 mmolll, despite treatment at the time with clofibrate. All patients consumed less than 6 units of alcohol per week. One patient (no. 11) had a raised ESR, but plasma viscosity, C-reactive protein mea surements and all other blood tests were normal. All patients except 1 had a good final visual acuity. Three patients had a BRVO and 2 had a CRVO.
DISCUSSION
The effects of the OCP and HRT on blood rheology and cardiovascular risk are different owing to the different dosages used. Discussion will therefore consider these two therapies separately.
The OCP has been shown to increase the risk of thromboembolism, as well as increasing risk for cardiovascular and cerebrovascular disease. 5 -7 This is the case even in patients with no other particular identifying risk factors. This effect is independent of other risk factors such as hypertension and smoking, although a combination of risk factors further increases the relative risk. 8 Given the close similarity between risk factors for RVO and cardiovascular and cerebrovascular disease, it is therefore reasonable to suspect that the OCP may predispose towards RVO. However, given the scarceness of reports in the literature of RVO in patients taking the OCP, and the relatively small numbers of RVO in younger patients, no study has provided evidence for a causal relationship. RVO When considering the epidemiological effects of OCP use, it is important to consider the changes in formulation, oestrogen dose and potencies over the last 30 years. Particularly significant is the reduction of the average oestrogen dose from 50 f,Lg to less than 30 f,Lg with modern 'low-dose' preparations. Some authors have suggested that with these newer preparations there may be no excess cardiovascular risk as noted in earlier studies.9 With regard to venous thrombbembolism, and cerebrovascular dis ease, the evidence is less clear. The powerful synergistic effect of smoking combined with OCP use for cardiovascular risk has also been noted. lO In this large series of patients with RVO there were 9 women aged under 35 years with RVO. Nationally, the uptake of the OCP in patients in this age group (25-34 years) was 30% of the population during the period of the study.II Thus by chance we would expect there to be 3 patients in this group taking the OCP. Instead, 6 of these 9 patients sustaining RVO were OCP users. This suggests a possible relationship, although numbers are too small for statistical interpretation. The inclusion of ex-users of the OCP in this study is important because although the excess cardiovascular risk is confined to current users, there is a past-use effect noted for cerebrovascular disease. 12 Survey of the literature shows only a small number of patients sustaining RVO while taking the OCP. These had generally been reported as isolated occurrences, and to date the largest number of cases in any other series was 2. However, anecdotal evidence suggests that this occurrence may make up a significant proportion of the young patients with RVO. Fong and Schatz1 3 commented that OCP associated RVO is a 'very rare occurrence, and is probably associated with other contributing factors' a view not supported by our findings.
The case in which the OCP was not stopped is an interesting example. This patient had an RVO, continued with the OCP, and later went on to develop a further RVO with a poor visual outcome. The rate of re-occlusion is usually low, particularly in young patients. This suggests that cessation of the OCP is an important part of the management of these patients.
There are several possible mechanisms for the effect of the OCP on RVO risk. First, the OCP has been shown to increase coagulability by increasing levels of fibrinogen and factor VIIC.1 4 .1 5 This effect is notably smaller in patients taking lower levels of oestrogen, but seems to be maintained for a period after cessation of the OCP. Hypertension is an important risk factor for RVO, although less so in young patients compared with an older cohort. It has been estimated that the OCP causes a rise in the diastolic blood pressure of 2 mmHg and a rise of 5 mmHg in systolic blood pressure.16 This is a small but significant elevation. Such an increase would be expected to elevate the risk of cerebral infarction and coronary heart disease by 1.5 and 1.2, respectively. The OCP is known to affect blood lipids, notably causing an increase in serum low density lipoprotein cholesterol (LDL) and a decrease in high density lipoprotein cholesterol (HDL).1 7 .1 8 Hyperlipidaemia has been shown to be the major identified risk factor for RVO in young patients. I9 In the HRT group of patients, an aetiological role for HRT is much less apparent. These patients are in an age group where RVO is considerably more common than in the younger group of patients. Seventy-one female patients between the ages of 40 and 60 years sustained an RVO, so these patients make up only 7% of this group, supporting the absence of an aetiological role for HRT. Addition ally, 4 of 5 patients had other well-established risk factors for RVO. These data provide no evidence that HRT does predispose to RVO. Their impor tance is in the increasingly widespread uptake of HRT, and the reduction of some contraindications, such as its use in hypertensive patients. 19 With a large and increasing proportion of the population using HRT, even a weak association may have significant effects on a susceptible population and it is important for any potential adverse effects to be reported?O Unopposed oestrogens used in HR T seem to be protective against cardiovascular disease. However, their use is currently restricted to patients without uterine tissue. They have beneficial effects on lipoprotein metabolism, causing a reduction in total and LDL cholesterol and an increase in HDL cholestero1.20 This effect on cardiovascular disease is, however, reduced by the inclusion of a progesto gen, which appears to be the agent responsible for adverse effects on blood lipoproteins?l Oestrogens themselves may, however, have an adverse effect by their effects on blood coagulation, notably on fibrinogen, factor VIlc and antithrombin 1Il. 22 It is currently unclear whether opposed oestrogen/ progestogen preparations are protective against cardiovascular disease, and with some preparations the risk of thromboembolism may actually be increased?O This observation leads to a management dilemma, particularly regarding unopposed oestro gens. Patients with RVO have been reported to have an excess mortality from cardiovascular disease, supporting the idea that the protective effect of oestrogens in HRT would be beneficial. Equally, if HRT is implicated in the aetiology of RVO, then, should the therapy be stopped as in 1980s manage ment? Evidence suggesting that HRT should be continued comes from a study of postmenopausal women who did not demonstrate a rise in blood pressure during prolonged (unopposed oestrogen) HRT.2 3 It would therefore appear that in view of its cardioprotective effect, HRT should be continued in patients who sustain RVO whilst taking this therapy.
CONCLUSION
This is the largest series of cases of RVO associated with sex hormone preparations. In our series, such patients make up the majority of young female patients sustaining RVO. This is obviously a matter of some concern, ' particularly as one of our patients had recurrence with poor visual outcome.
Regarding patients with RVO taking HRT, there appears to be no obvious relationship between RVO and HRT. With the large and increasing number of patients using HRT in this country and world-wide, this has wider implications. Hence, it is important to report such patients, particularly as the epidemiolo gical effects of opposed HRT have yet to become fully apparent.
The mechanism for an increased risk of RVO with sex hormone preparations is unknown. Considering their effects on plasma lipoproteins and blood coagulability, with the prominence of the former as a risk factor for RVO in younger patients, both these detrimental effects of sex hormone preparations may have a significant role.
On the basis of the available (limited) data, it would seem prudent to stop the use of the oral contraceptive pill in patients sustaining retinal vein occlusion. However, our data do not suggest that use of hormone replacement therapy is associated with any excess risk of retinal vein occlusion.
